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Abstract
Induced pluripotent stem cells (iPSCs) hold enormous potential for the development of personalized in vitro disease models,
genomic health analyses, and autologous cell therapy. Here we describe the generation of T lymphocyte-derived iPSCs from
small, clinically advantageous volumes of non-mobilized peripheral blood. These T-cell derived iPSCs (‘‘TiPS’’) retain a
normal karyotype and genetic identity to the donor. They share common characteristics with human embryonic stem cells
(hESCs) with respect to morphology, pluripotency-associated marker expression and capacity to generate neurons,
cardiomyocytes, and hematopoietic progenitor cells. Additionally, they retain their characteristic T-cell receptor (TCR) gene
rearrangements, a property which could be exploited for iPSC clone tracking and T-cell development studies.
Reprogramming T-cells procured in a minimally invasive manner can be used to characterize and expand donor specific
iPSCs, and control their differentiation into specific lineages.
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Introduction
In vitro reprogramming of somatic cells to an undifferentiated
pluripotent state by viral transfer of defined factors such as
SOX2, OCT4, NANOG and LIN28 or SOX2, OCT4, c-Myc,a n d
KLF4[1,2] has opened the way for the generation of patient-
specific human iPSCs using multiple cell types [3,4]. This
premise has been further advanced by derivation of iPSCs via
transient expression of genes or by using protein transduction of
appropriate transcription factors [5,6]. To date, the majority of
iPSC research in humans has focused on fibroblasts as a cell
source. While fibroblasts offer certain advantages as a starting
material due to their commercial availability and ease of gene
delivery, they are suboptimal for large-scale clinical derivation
of iPSC lines due to the need for invasive skin biopsies and the
difficulty of establishing stable lines from primary tissue. Non-
mobilized peripheral blood is per h a p st h ei d e a lc e l ls o u r c ef o r
reprogramming due to the ease of obtaining patient samples [7].
Additionally, large numbers of frozen blood samples, from living
and deceased donors, are stored in biorepositories worldwide
[8].
Investigators have recently reported successful reprogramming
of primary CD34
+ hematopoietic progenitor cells from both
mobilized and non-mobilized blood donors [3,9]. These findings
represent an important advance in iPSC research, however, non-
mobilized adult peripheral blood contains approximately 100–
1000 CD34
+ cells/ml [10,11] making these rare progenitors a
challenging cell source for iPSC line derivation from small blood
volumes. As an alternative, more abundant and tractable blood
cell source we report the derivation of iPSCs from T lymphocytes
obtained from the equivalent of 1 ml whole blood. These T-cell
derived iPSCs (‘‘TiPS’’) share essential characteristics with hESCs
as well as fibroblast-derived iPSC lines. Additionally, they retain
their characteristic T-cell receptor (TCR) gene rearrangements, a
property which could be exploited, for example, as a genetic
tracking marker or in re-differentiation experiments to study
human T-cell development.
Results and Discussion
T-cells are well suited as a starting material for reprogramming
due to their abundance in whole blood (,6.5610
5–3.1610
6/ml in
healthy adults) [12] and ease of culture using well-established
protocols [13,14]. To facilitate T-cell proliferation and efficient
retroviral transduction, peripheral blood mononuclear cells
(PBMCs) were isolated from a leukapheresis or a standard
venipuncture (Vacutainer CPT tube) and cultured in serum-
free media with IL-2 and anti-CD3 antibody (Figure 1). This led to
preferential expansion of mature CD3+ T-cells consisting of an
average day 3 CD3
+ purity of 90% +/2 7% (Figure 2A).
Activated T-cell enriched populations containing 1610
6 cells
were subjected to two rounds (at day 0 and 1) of retroviral
transduction with four separate vectors, each encoding one of the
reprogramming factors (SOX2, OCT4, c-Myc,o rKLF4) linked to a
fluorescent marker gene. Transduction efficiency was assessed at
day 3 by fluorescence microscopy and flow cytometry. Staining for
CD3 showed the transduced population to be 99% +/2 1% CD3
+
(Figure 2A).
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placed on irradiated mouse embryonic fibroblasts (MEFs) in hESC
medium supplemented with 100 ng/ml basic fibroblast growth
factor (bFGF). iPSC colonies were observed beginning at day 23.
Reprogramming efficiencies of T-cells were estimated by dividing
the number of colonies with hESC-like morphology by the input
number of transduced cells and determined to be approximately
0.01%, similar to published fibroblast and CD34
+ cell efficiencies
[1,3].
TiPS were generated from both leukapheresis samples (from a
male Hispanic adult, lines denoted ‘‘TiPS-L’’) and whole blood
Vacutainer samples (from a male Caucasian adult, lines denoted
‘‘TiPS-V’’). In each case, reprogramming was achieved using an
input cell number equivalent to the amount of T-cells in 1 ml whole
blood. Colonies displaying hESC morphology were expanded on
MEFs and the clones were successfully maintained under feeder-
free conditions using mTeSR media and Matrigel coated plates.
We performed DNA fingerprinting to verify that TiPS shared a
genetic background with the starting donor T-cell population and
to rule out cell line cross-contamination (Figure S1). Pluripotency
was verified by expression of hESC pluripotency markers SSEA-3,
SSEA-4, Tra-1-81, and OCT4 using flow cytometry (Figure 2B)
and alkaline phosphatase staining (Figure S2). We confirmed the
TiPS lines’ T-cell origin via multiplex PCR detection of TCR b
chain rearrangements (Figure 2C).
RT-PCR was performed to confirm expression of hESC genetic
markers DNMT38, LEFT8, NODAL, REX1, ESG1, TERT, GDF3,
and UTF1 (Figure 3A). Further characterization demonstrated
integration of the transgenes into the host genome as well as their
silencing following successful reprogramming (Figures 3B, C).
TiPS were similar to both the hESC line H1 and to fibroblast-
derived iPSC line controls in all of the above assays. Additionally,
lines were karyotypically normal after multiple passages and have
been propagated for over 30 passages in culture while retaining a
normal karyotype (Figure S3).
Finally, the TiPS cell lines were evaluated to determine their in
vivo and in vitro differentiation potential. All TiPS clones formed
teratomas. The teratomas contained tissue consistent with
derivation from all three primary germ layers (Figures 4A). The
cell lines were also assessed for their capability to differentiate in
vitro into ectodermal and mesodermal lineages in various directed
differentiation protocols. The clones were able to generate
neurons, beating cardiac troponin T-positive cardiomyocytes and
multipotent granulocyte-erythroid-macrophage-megakaryocyte
(GEMM) hematopoietic cells (Figures 4B, C, D, E).
A potential concern of T-cell derived iPSCs is the persistence of
TCR gene rearrangements in the iPSC genome and their potential
effect on subsequent differentiation. Though we did not observe
any significant differences in differentiation potential between
TiPS clones and hESC lines or fibroblast-derived iPSC lines
(Figure 4D,E, additional data not shown) the effects of these
genomic rearrangements on lymphoid differentiation remain to be
investigated. TCR rearrangements may in fact prove advanta-
geous in certain contexts, such as for iPSC clone tracking, as
demonstrated by the detection of parent line clonal TCR b chain
rearrangements in derivative teratomas (Figure 5). Further, upon
re-differentiation into T-cells TiPS cells may bypass key steps in the
canonical thymic development sequence due to the mechanism of
TCR allelic exclusion caused by the expression of their pre-
rearranged TCR genes. This phenomenon could be explored in
T-cell development studies.
It should be noted that insertional mutagenesis and other
potential disruptions of cellular function are possible when using a
retroviral reprogramming protocol [15]. Recent advances in using
episomal reprogramming methods may address these issues and
efforts are in progress to reprogram T-cells via these alternative
methods [5,6]. Further, an interesting example of a potential
therapeutic use for such episomally reprogrammed TiPS cells is as
a source to differentiate integration-free hematopoietic stem cells
bearing endogenous TCR genes specific for tumor-associated
antigens [16].
Previous reports of reprogramming terminally differentiated B
lymphocytes in mice required the addition, or knock-down, of
cellular identity-associated transcription factors and used a
doxycycline-inducible expression system [17]. Recently, a descrip-
tion of reprogramming murine T-cells was published necessitating
a p53 gene knock-out for successful iPSC generation [18].
Experiments involving manipulation of anti-proliferative pathways
[19,20,21,22] offer insights into the mechanisms of reprogram-
ming and may significantly augment reprogramming efficiencies.
However, none of the above mentioned manipulations appear to
be a requirement for successful viral reprogramming of human T-
cells. Additionally, our data, coupled with methodologies used in
reprogramming adult CD34+ hematopoietic progenitor cells [3,9],
now afford a primary, human system to examine recent
observations in the mouse system correlating differentiation stage
of input cells with reprogramming efficiency [23].
We describe the derivation of iPSCs from small, clinically
advantageous volumes of non-mobilized human peripheral blood.
T-cells represent an abundant cell source for reprogramming
which can be harvested from large numbers of donors in a
minimally invasive manner and cultured via well-established
protocols. In the experiments we have detailed, TiPS have similar
characteristics and differentiation potential as hESC lines and
Figure 1. Overview of T-cell reprogramming process, beginning with activated T-cells and resulting in iPSC colonies with hESC-like
morphology. T-cell and iPSC colony images were acquired on an Olympus IX71 microscope with 106and 206objectives, respectively.
doi:10.1371/journal.pone.0011373.g001
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model with which to explore iPSC clone tracking, T-cell
development and therapeutic applications of iPSC technology.
Materials and Methods
Cell Growth Media and Basic Fibroblast Growth Factor
iPSC lines were maintained using previously described methods
[1]. Zebrafish bFGF was substituted for human bFGF in all
experiments, as previously described [24].
Fibroblast iPSC Lines
Control fibroblast-derived iPSC lines, referred to as ‘‘Fib-iPS’’,
were produced as previously described using IMR90 cells obtained
from ATCC (Manassas, VA) [1].
T-cell Activation and Expansion
Peripheral Blood Mononuclear Cells (PBMCs) were obtained
from an HLA-A2 positive adult male Hispanic donor (‘‘Donor L’’)
leukocyte pack (Biological Specialty Corp, Colmar, PA) processed
with Lymphocyte Separation Medium (Cellgro, Manassas, VA).
Additionally, whole blood samples were collected from a male
Caucasian donor of unknown serotype (‘‘Donor V’’) via standard
venipuncture in a Vacutainer CPT
TM tube (BD Biosciences, San
Jose, CA) and PBMCs were collected by centrifugation according
to the manufacturer’s recommendations. Blood samples were
obtained with written informed consent in accordance with the
Declaration of Helsinki and Institutional Review Board approval
from the Biological Specialty Corporation (Colmar, PA, USA). T-
cells were expanded in freshly prepared AIM-V Medium
(Invitrogen, Carlsbad, CA) supplemented with pen/strep/gluta-
mine (Invitrogen) plus 300 IU/ml rhIL2 (Peprotech, Rocky Hill,
NJ) and 10 ng/ml soluble anti-CD3 antibody (eBioscience, OKT3
clone, San Diego, CA) [25,26] Proliferation was verified by
CEDEX (Roche Innovatis, Bielefeld, Germany) cell count after 3
days in culture at which point cells were assayed for T-cell
phenotype and then transduced with reprogramming factors.
Transient Transfection for Retrovirus Production
Retrovirus was generated by transfecting 293T cells in a 10 cm
plate at 70-80% confluence with 10 ug of retroviral vector
(Moloney Murine Leukemia Virus) backbone encoding each of 4
Figure 2. Derivation and characterization of induced pluripotent stem cells from human T-cells. (A) Flow cytometric analysis of input cell
source CD3 surface expression. (i) CD3 surface expression on day -3 non-activated PBMCs and day 0 activated T-cells from the PBMC population in a
representative donor. (ii) CD3 expression gated on the transduced (GFP
+) cell population 72 hours post-transduction in a representative donor to
demonstrate preferential transduction of CD3
+ cells. (iii) Histogram representation of the above metrics (i-ii) in an average of 10 donor Vacutainer-
derived samples. (B) Flow cytometric analysis of hESC pluripotency markers OCT4, Tra-1-81, SSEA-3 and SSEA-4 in representative leukapheresis (‘‘TiPS
L-2’’) and Vacutainer (‘‘TiPS V-1’’) derived TiPS lines. (C) T-cell receptor (TCR) b chain rearrangement analysis using multiplexed PCR primers targeted
to conserved regions within the V-J region of the TCR b locus. Polyclonal starting T-cell populations are represented by a bell-shaped curve of
amplicon peaks within the valid fragment size range on the electropherogram. Fibroblast (non-T-cell) iPS cells (‘‘Fib-iPS’’) lack germline
rearrangement at the TCR b locus and serve as a negative control. The clonally derived TiPS lines (representative data from two leukapheresis lines
and one Vacutainer line, ‘‘TiPS L-1’’, ‘‘TiPS L-2’’ and ‘‘TiPS V-2’’, respectively) show one distinct peak of defined size. DNA fragment analysis was
performed on an ABI 3730 DNA analyzer.
doi:10.1371/journal.pone.0011373.g002
Figure 3. Characterization of induced pluripotent stem cells from human T-cells. (A) RT-PCR analysis of representative leukapheresis (‘‘TiPS
L-1’’ and ‘‘TiPS L-2’’) and Vacutainer (‘‘TiPS V-2’’) derived TiPS cell lines for expression of hES cell-marker genes DNMT38, LEFTB, NODAL, REX1, ESG1,
TERT, GDF3, and UTF1. GAPDH was used as positive loading control for each sample. (B) PCR analysis of genomic DNA confirms integration of the
transgenes. Forward primers for the reprogramming gene (‘‘RG’’) of interest and reverse primers for the IRES were utilized. OCT4 forward and reverse
primers were used as the PCR reaction positive control, as shown in vector map. (C) RT-PCR analysis of TiPS cell lines shows silencing of the
exogenous transgenes, with GAPDH as positive control for each sample. In (A) and (C) hESC line H1 and in (A-C) a fibroblast derived iPSC line (‘‘Fib-
iPS’’) served as positive cell controls, and activated donor T-cells served as a negative cell control. In (A-C) images were modified with Photoshop
software to combine gels and remove redundant control data from separate experiments.
doi:10.1371/journal.pone.0011373.g003
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PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11373Figure 4. In vivo and in vitro differentiation potential of TiPS cell lines. (A) Teratoma formation shows in vivo differentiation potential. TiPS
cells injected into SCID/beige mice formed teratomas at 5 to 12 weeks. Hematoxylin and eosin staining shows tissues consistent with derivation from
the three primary germ layers including simple epithelium with goblet cells indicating gastrointestinal or respiratory tissue (endoderm), cartilage
(mesoderm) and retinal pigmented epithelium (ectoderm). Representative images from TiPS L-2 cell line were acquired using an Olympus IX71
microscope using a 406objective. (B) In vitro differentiation into neurons. TiPS L-2 cells were induced into neuronal differentiation as aggregates
then stained for neuronal marker beta III-tubulin with an Alexa Fluor 594 secondary antibody; cell nuclei were counterstained with Hoechst stain.
Images were acquired using a 206objective. Contrast was adjusted and images were merged using Image J software. (C) Cardiac induction of TiPS
cells via cell aggregate method. Cell aggregates contain beating cardiac troponin T (cTNT)-positive cardiomyocytes at days 14 to 15. Flow data from
representative samples is shown. Images were acquired using a 106 objective. (D) In vitro differentiation into hematopoietic progenitor cells.
Hematopoietic progenitor cells (HPCs) generated via a serum-free embryoid body (EB) differentiation protocol for 12 days in two TiPS lines compared
to an hESC line (‘‘H1’’) and a fibroblast derived iPSC line (‘‘Fib-iPS’’). HPCs were quantified via flow cytometry by dissociating the EBs into single cells
and staining with fluorochrome-conjugated monoclonal antibodies to CD34, CD45, CD43, CD31, CD41 and CD235a. (E) Hematopoietic clonogenic
iPSCs from Human T-Cells
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RFP), 3 ug of Gag-Pol, 1 ug of plasmid encoding a derivative of
NFkB, and 1 ug of Vesicular Stomatitis Virus G protein using
polyethylene imine (‘‘PEI’’) lipophilic reagent (40 ug/10 cm plate).
After four hours, the medium was exchanged with 5 ml of DMEM
(Invitrogen) plus 10% FBS (Hyclone, Waltham, MA) and 50 mM
HEPES (Invitrogen). Viral supernatant was collected 48 hours
post-transfection and passed through a 0.8 um pore size filter.
Retroviral Transductions via Spinfection
One million activated donor cells per well were ‘‘spinfected’’ via
centrifugation for 1.5 h61000 g at 32uC in a mixture of the four
retroviral supernatants plus 4 ug/ml polybrene (Sigma-Aldrich, St.
Louis, MO), and 300 IU/ml rhIL-2. After spinfection the plates
received a half-media exchange, and were incubated overnight.
The next day the cells were harvested by centrifugation and
spinfected a second time.
Verification of T-cell Expansion and Transduction
Efficiency
T-cell identity was verified 3 days after activation by flow
cytometry surface staining with anti-CD3 antibodies (BD, clone
HIT3a), as well as post-transduction to verify which cell
population was transduced successfully. Samples were run on an
(CFU) assays were performed by placing EB differentiated and individualized cells into serum-free MethoCult media containing cytokines (SCF, G-CSF,
GM-CSF, IL-3, IL-6, and EPO). Colonies were scored after 14 days of incubation according to morphologic criteria as erythroid (CFU-E/BFU-E), myeloid
comprising macrophage (CFU-M), granulocyte (CFU-G), and granulocyte-macrophage (CFU-GM), and multilineage comprising granulocyte-erythroid-
macrophage-megakaryocyte (CFU-GEMM) colonies. Total CFUs were quantified and representative images were acquired using an Olympus CKX41
microscope with a 26objective.
doi:10.1371/journal.pone.0011373.g004
Figure 5. iPSC Clone Tracking. Genomic DNA was isolated from teratoma samples and compared with their parent cell lines for TCR b chain
rearrangements. Representative data is shown from cell line TiPS V-1. The derivative teratoma harbors the clonal rearrangement of the parent cell
line. PCR analysis was conducted using multiplexed primers targeted to conserved regions within the V-J region of the TCR b locus. DNA fragment
analysis was performed on an ABI 3730 DNA analyzer. Background #1000 RFU.
doi:10.1371/journal.pone.0011373.g005
iPSCs from Human T-Cells
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conducted on days 0, 3 and 4 to confirm expansion and thus
amenability to MMLV retroviral infection (data not shown).
Plating Transduced T-cells on MEFs
Seventy two hours post initial transduction, transduction success
and efficiency estimates were verified by fluorescent microscopy
and flow cytometry as listed above. 5610
5 transduced cells were
added to 10 cm plate seeded with MEFs 1 to 3 days prior in a 50/
50 media combination D10F:hESC without zbFGF (or additional
cytokines). Cells were incubated and fed hESC media + 100 ng/
ml zbFGF (first week) or MEF-conditioned media + 100 ng/ml
zbFGF (thereafter) by half media exchange every other day. To
avoid cell loss during feedings the plates were angled slightly for 10
minutes to allow the cells to settle and media was removed slowly
from the media horizon.
iPSC Colony Identification and Picking
Colonies with well-defined borders and typical hESC morphol-
ogy began to appear around day 23. GFP and RFP silencing was
verified by fluorescent microscopy and the number of colonies was
counted to estimate reprogramming efficiency given the number of
input plated cells. Colonies were manually harvested, transferred
to MEFs, and expanded according to established protocols [7,27]
Estimates of reprogramming efficiency were obtained by dividing
total number of putative iPSC colonies by the input number of
transduced cells. Counts were ceased after colony harvest (day 25–
30) to avoid the inclusion of false positive re-seeded colonies left
behind from the harvest.
DNA Fingerprinting
TiPS cell lines and donor PBMCs were sent to the University of
Wisconsin Histocompatibility/Molecular Diagnostics Laboratory
(Madison, WI) for short tandem repeat (STR) analysis. Genotypes
for 8 STR loci were determined from TiPS cell sample DNA.
Karyotyping
G-banding analysis was conducted by WiCell Research Institute
(Madison, WI).
T-cell Receptor b Chain Rearrangement Analysis
Genomic DNA was isolated per manufacturer’s protocol (using
the Qiagen DNeasy Blood and Tissue kit) from donor T-cells, the
TiPS cell lines, and a fibroblast (non-T-cell) derived iPSC line used
as a negative control. Additionally, DNA was isolated from frozen
teratoma samples and parent cell lines by first dissolving tissue and
cell samples in a buffer containing Tris, NaCl, EDTA, SDS and
Proteinase K (Invitrogen). DNA was then precipitated with
saturated NaCl and ethanol, and resuspended in water for PCR
analysis. PCR was performed using a multiplex primer kit
(Invivoscribe Technologies, San Diego, CA) specific for a majority
of clonal TCR b chain rearrangements [28]. Capillary electro-
phoresis and PCR product fragment analysis was performed at the
University of Wisconsin Biotechnology Center DNA Sequencing
Core Facility (Madison, WI) using an ABI 3730 DNA analyzer.
Data was analyzed using Peak Scanner software (ABI, Foster City,
CA).
Alkaline Phosphatase (AP) Staining
Confluent cells grown on MEFs were AP stained with Vector
Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories,
SK-5300, Burlingame, CA) according to the manufacturer’s
protocol.
RT-PCR for Transgene and hESC Marker Gene Expression
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Germantown, MD) according to the manufacturer’s protocol. First
strand cDNA synthesis was carried out with oligo-dT primers (as
described previously [1,2]) using SuperScript III First Strand
Synthesis kit (Invitrogen) according to the product protocol. cDNA
was diluted 1:2 and PCR reactions were performed with GoTaq
Green Master Mix (Promega, Madison, WI) using a Mastercyler
(Eppendorf, Hauppauge, NY).
PCR Analysis of Viral Integration
Genomic DNA was isolated from 1–5610
6 iPSCs using DNeasy
Blood and Tissue kit (Qiagen) according to the manufacturer’s
protocol for cultured cells. Genomic DNA (5 ul) was used for PCR
reactions to check for viral integration using GoTaq Green Master
Mix (Promega). Specific primer sets were used that detect only the
transgene and not the endogenous gene. Primers for endogenous
OCT4 served as a positive control for the reaction. Reactions were
performed with primers as described previously [1,2].
Flow Cytometry: iPSC Line Intracellular and Surface
Pluripotency Marker Characterization
TiPS maintained on Matrigel were harvested and stained for
the presence of Tra-1-81(BD Pharmingen or Stemgent, San
Diego, CA, both clone Tra-1-81), SSEA-3 (BD Pharmingen, clone
MC631) and SSEA-4 (BD Pharmingen, clone MC813-70).
Intracellular OCT4 (BD, clone 40/Oct-3) staining was performed
on cells fixed with 2% paraformaldehyde and permeablized with
PBS + 0.1% saponin. Cells were stained overnight and analyzed
the next day on an Accuri flow cytometer.
Hematopoietic Differentiation and Colony-Forming Unit
Assays
Undifferentiated TiPS were adapted to feeder-free conditions
on Matrigel coated plates and maintained using mTeSR medium
(Stem Cell Technologies, Vancouver BC, Canada). The colonies
were harvested using TrypLE (Invitrogen) and placed in serum-
free embryoid body (EB) basal media [containing IMDM, NEAA,
Glutamine (Invitrogen) and 20% BIT-9500 (Stem Cell Technol-
ogies) and ROCK inhibitor H1152] in low-attachment plates to
facilitate aggregate formation. Following aggregate formation, the
cells were placed in EB basal media supplemented with growth
factors and cytokines: rhBMP-4 (R&D Systems, Minneapolis,
MN), rhVEGF, zbFGF, rhFlt-3 ligand, rhIL-3, and rhGM-CSF
(Invitrogen) for 12 days. The cells were harvested and the
phenotype generated by each iPSC clone was assessed by surface
staining for CD31, CD34, CD43, CD45, CD41 and CD235a by
flow cytometry. The individualized cells were placed in MethoCult
(Stem Cell Technologies) media for quantifying colony-forming
units per the manufacturer’s instructions.
Assay for Teratoma Formation
Characterized iPSCs cultured on MEFs were injected
intramuscularly into the hind limb of SCID/beige mice (Harlan
Laboratories, Madison, WI). Three mice were injected per cell
line, each with one 6-well plate of cells. Matrigel (BD
Biosciences) was added at 1/3 total volume to the cell suspension
prior to injection. Tumors formed at 5 to 12 weeks and were
processed for hematoxylin and eosin staining and histological
analysis by the McArdle Laboratory for Cancer Research
(University of WI-Madison). All animal work was conducted
according to relevant national and international guidelines under
iPSCs from Human T-Cells
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Cardiac Differentiation
Cardiogenesis was induced via a cell aggregate method. Briefly,
TiPS cells grown on MEFs were harvested with collagenase IV
(Invitrogren) and cells grown on Matrigel were dissociated into
single cell suspension using Sodium Citrate. The cell suspension
was allowed to form aggregates in ultra-low attachment flasks in
the presence of recombinant human hepatocyte growth factor
(HGF) and/or zbFGF. Additionally, ROCK inhibitor H1152 was
added to Matrigel-sourced cell suspensions. Beating aggregates
were dissociated and stained for cardiac troponin T (cTnT)
(Abcam, Cambridge, MA, clone 1C11) on days 14 to 15.
Neuronal Differentiation
The neural differentiation of TiPS cells was performed as
previously described [29]. Briefly, TiPS grown on MEFs were
partially dissociated with collagenase IV and cultured in
suspension as aggregates in Stemline Neural Stem Cell Expansion
Medium (Sigma-Aldrich) supplemented with B27 supplement
(Invitrogen), bFGF (100 ng/ml) and epidermal growth factor
(100 ng/ml, Chemicon, Billerica, MA). Cultures were passaged
weekly using a McIlwain tissue chopper. To induce neural
differentiation, spheres were grown in neural induction medium
(DMEM/F12 plus N2 supplement, Invitrogen) for one week and
then plated onto poly-ornithine/laminin (Sigma-Aldrich)-coated
coverslips in the same neural induction medium supplemented
with cAMP (1 uM, Sigma-Aldrich), ascorbic acid (200 ng/ml,
Sigma-Aldrich), brain-derived neurotrophic factor and glial cell
line-derived neurotrophic factor (both 10 ng/ml, R&D Systems)
for a further 3 weeks. The expression of neuronal maker beta III-
tubulin was analyzed by immunofluorescence staining as previ-
ously described [30].
Supporting Information
Figure S1 DNA Fingerprinting. Short Tandem Repeat (STR)
analysis shows TiPS cell lines are identical to parent activated T-
cells for all 15 allelic polymorphisms detected across the 8 STR
loci analyzed. Representative data from two TiPS lines (TiPS L-1
and TiPS L-2) are shown.
Found at: doi:10.1371/journal.pone.0011373.s001 (3.65 MB TIF)
Figure S2 Alkaline Phosphatase (AP) Staining. TiPS lines TiPS
L-1 and TiPS L-2 are AP positive. Images were acquired on an
HP Scanjet G3110 computer scanner.
Found at: doi:10.1371/journal.pone.0011373.s002 (2.87 MB TIF)
Figure S3 TiPS cell lines display normal karyotype. TiPS cell
lines ‘‘TiPS L-1’’ and ‘‘TiPS L-2’’ were grown for 6 passages on
MEFs, and lines ‘‘TiPS V-1’’ and ‘‘TiPS V-2’’ were grown on
Matrigel for 8 of 18 total passages and 30 of 34 total passages,
respectively. Cells were subjected to G banding analysis and no
clonal abnormalities were detected.
Found at: doi:10.1371/journal.pone.0011373.s003 (4.70 MB TIF)
Figure S4 Vector map of the MMLV retroviral construct used
for reprogramming experiments. ‘‘RG’’ denotes reprogramming
gene.
Found at: doi:10.1371/journal.pone.0011373.s004 (1.91 MB TIF)
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